Company: CMND
Filing Date: 2025-11-19
Form Type: 424B5
Source: 0001213900-25-112329
Chunk: 35

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-19
Form: 424B5
Chunk 35
---
 We report under International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards
Board, or IASB. None of the financial statements were prepared in accordance with generally accepted accounting principles in the United
States, or U.S. GAAP.

Certain
figures included in this prospectus have been subject to rounding adjustments. Accordingly, figures shown as totals in certain tables
may not be an arithmetic aggregation of the figures that precede them.

On September 30, 2022, we
effected a one-for-30 consolidation of our issued and outstanding Common Shares. In addition, on November 28, 2023, we effected a one-for-30
consolidation of our issued and outstanding Common Shares. Except where otherwise indicated, all share and per share data in this prospectus
have been retroactively restated to reflect the aforementioned consolidations.

<div align='center'>TRADEMARKS AND TRADENAMES</div>

We own or have rights to trademarks,
service marks and trade names that we use in connection with the operation of our business, including our corporate name, logos and website
names. Other trademarks, service marks and trade names appearing in this prospectus are the property of their respective owners. Solely
for convenience, some of the trademarks, service marks and trade names referred to in this prospectus are listed without the and
™ symbols, but we will assert, to the fullest extent under applicable law, our rights to our trademarks, service marks and trade
names.

<div align='center'>3

OUR BUSINESS</div>

Company Overview

We are a pharmaceutical company
that develops novel psychedelic medicines to solve widespread, yet under-served, health problems. Our goal is to develop and provide a
new type of treatment for mental health disorders, including alcohol use disorders, or AUD, binge drinking and eating disorders, where
there is significant unmet need and lack of innovation. We see psychedelic therapies, which previously may have been overlooked or underused,
as the future of treatment for a variety of indications. We believe that our solution for AUD can help solve one of the world’s
biggest health problems, which costs the United States alone roughly $250 billion each year.

Our flagship treatment and
focus for the short term is on AUD, which is incredibly common. It varies from mild to excessive and describes a person’s inability
to restrict their alcohol consumption, despite negative social, occupational, or health consequences. Alcohol consumption contributes
to 3 million deaths